BRPI0908098A2 - Beloxepina, composição, métodos para tratar dor em um mamífero, para inibir a recaptação de ne, para antagonizar um receptor de 5ht2 e para tratar um distúrbio em um paciente que é responsivo ao tratamento com um composto nri e com um composto antagonista de 5ht2 - Google Patents
Beloxepina, composição, métodos para tratar dor em um mamífero, para inibir a recaptação de ne, para antagonizar um receptor de 5ht2 e para tratar um distúrbio em um paciente que é responsivo ao tratamento com um composto nri e com um composto antagonista de 5ht2Info
- Publication number
- BRPI0908098A2 BRPI0908098A2 BRPI0908098-8A BRPI0908098A BRPI0908098A2 BR PI0908098 A2 BRPI0908098 A2 BR PI0908098A2 BR PI0908098 A BRPI0908098 A BR PI0908098A BR PI0908098 A2 BRPI0908098 A2 BR PI0908098A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- compound
- beloxepine
- antagonizing
- reuptake
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 title 1
- 108091005479 5-HT2 receptors Proteins 0.000 title 1
- 241000124008 Mammalia Species 0.000 title 1
- 230000003042 antagnostic effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2991508P | 2008-02-19 | 2008-02-19 | |
| US2991308P | 2008-02-19 | 2008-02-19 | |
| US2991608P | 2008-02-19 | 2008-02-19 | |
| US5092108P | 2008-05-06 | 2008-05-06 | |
| PCT/US2009/034461 WO2009105507A2 (en) | 2008-02-19 | 2009-02-19 | Beloxepin, its enantiomers, and analogs thereof for the treatment of pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0908098A2 true BRPI0908098A2 (pt) | 2015-08-18 |
Family
ID=40986169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0908098-8A BRPI0908098A2 (pt) | 2008-02-19 | 2009-02-19 | Beloxepina, composição, métodos para tratar dor em um mamífero, para inibir a recaptação de ne, para antagonizar um receptor de 5ht2 e para tratar um distúrbio em um paciente que é responsivo ao tratamento com um composto nri e com um composto antagonista de 5ht2 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP2285818A4 (enExample) |
| JP (1) | JP2011512414A (enExample) |
| KR (1) | KR20100137473A (enExample) |
| CN (1) | CN102007139A (enExample) |
| AU (1) | AU2009215541A1 (enExample) |
| BR (1) | BRPI0908098A2 (enExample) |
| CA (1) | CA2715192A1 (enExample) |
| IL (1) | IL207668A0 (enExample) |
| MX (1) | MX2010009110A (enExample) |
| NZ (2) | NZ594937A (enExample) |
| WO (1) | WO2009105507A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090233959A1 (en) | 2008-02-19 | 2009-09-17 | Adolor Corporation | Beloxepin and analogs for the treatment of pain |
| EP3632434A1 (en) * | 2015-02-25 | 2020-04-08 | The Regents of the University of California | The 5ht agonist clemizole for use in treating disorders |
| CN106243096B (zh) * | 2016-07-29 | 2019-11-29 | 上海璃道医药科技有限公司 | 三环类药物的新用途 |
| US10966938B2 (en) | 2019-01-04 | 2021-04-06 | Jonand4, Llc | Composition and method for preventing or treating hangover symptoms |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE62754B1 (en) * | 1988-08-26 | 1995-02-22 | Akzo Nv | Tetracyclic antidepressants |
| US5663178A (en) | 1995-02-06 | 1997-09-02 | Eli Lilly And Company | Tetrahydro-beta carbolines |
| US5952331A (en) | 1996-05-23 | 1999-09-14 | Syntex (Usa) Inc. | Aryl pyrimidine derivatives |
| TW440563B (en) | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
| GB0004003D0 (en) * | 2000-02-22 | 2000-04-12 | Knoll Ag | Therapeutic agents |
| GB0019950D0 (en) | 2000-08-12 | 2000-09-27 | Smithkline Beecham Plc | Compounds |
| EA200500783A1 (ru) * | 2002-12-11 | 2005-12-29 | ФАРМАЦИЯ ЭНД АПДЖОН КОМПАНИ ЭлЭлСи | Комбинация для лечения синдрома дефицита внимания с гиперактивностью |
| JP2007510642A (ja) * | 2003-11-03 | 2007-04-26 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 中枢神経系障害の治療のための新規ノルエピネフリン再取込み阻害薬 |
| CN101084205A (zh) * | 2004-12-13 | 2007-12-05 | 艾尼纳制药公司 | 作为5ht2c受体调节剂以治疗与其相关病症的n－联芳基和n－芳基杂芳基哌嗪衍生物 |
| CN101107254B (zh) * | 2005-01-27 | 2010-12-08 | 詹森药业有限公司 | 在中枢神经系统病症的治疗中作为5ht2抑制剂的杂环四环四氢呋喃衍生物 |
| WO2006105117A2 (en) * | 2005-03-28 | 2006-10-05 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
| CA2624096A1 (en) * | 2005-09-29 | 2007-04-12 | Wyeth | Benzothiadiazolyphenylalkylamine derivatives for use in the treatment of conditions ameliorated by monoamine reuptake |
| EP2015765A4 (en) * | 2006-03-28 | 2011-11-23 | Neopro Labs Llc | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS |
| GB0608655D0 (en) * | 2006-05-03 | 2006-06-14 | Merck Sharp & Dohme | Therapeutic Treatment |
| WO2007142923A1 (en) * | 2006-05-31 | 2007-12-13 | Avigen, Inc. | Mif inhibitors for treating neuropathic pain and associated syndromes |
-
2009
- 2009-02-19 CA CA2715192A patent/CA2715192A1/en not_active Abandoned
- 2009-02-19 EP EP09712730A patent/EP2285818A4/en not_active Withdrawn
- 2009-02-19 NZ NZ594937A patent/NZ594937A/xx not_active Application Discontinuation
- 2009-02-19 JP JP2010547737A patent/JP2011512414A/ja not_active Withdrawn
- 2009-02-19 WO PCT/US2009/034461 patent/WO2009105507A2/en not_active Ceased
- 2009-02-19 NZ NZ587896A patent/NZ587896A/en not_active IP Right Cessation
- 2009-02-19 CN CN2009801138213A patent/CN102007139A/zh active Pending
- 2009-02-19 BR BRPI0908098-8A patent/BRPI0908098A2/pt not_active IP Right Cessation
- 2009-02-19 MX MX2010009110A patent/MX2010009110A/es not_active Application Discontinuation
- 2009-02-19 AU AU2009215541A patent/AU2009215541A1/en not_active Abandoned
- 2009-02-19 KR KR1020107021010A patent/KR20100137473A/ko not_active Withdrawn
-
2010
- 2010-08-18 IL IL207668A patent/IL207668A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011512414A (ja) | 2011-04-21 |
| WO2009105507A2 (en) | 2009-08-27 |
| IL207668A0 (en) | 2010-12-30 |
| EP2285818A2 (en) | 2011-02-23 |
| CA2715192A1 (en) | 2009-08-27 |
| KR20100137473A (ko) | 2010-12-30 |
| AU2009215541A1 (en) | 2009-08-27 |
| NZ587896A (en) | 2011-09-30 |
| NZ594937A (en) | 2013-03-28 |
| EP2285818A4 (en) | 2011-08-17 |
| WO2009105507A3 (en) | 2010-01-14 |
| CN102007139A (zh) | 2011-04-06 |
| MX2010009110A (es) | 2010-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1009381A2 (pt) | compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêutica | |
| BRPI0719276A2 (pt) | Métodos para tratar, prevenir ou controlar uma doença associada com uma mutação sem sentido, para tratar, prevenir ou reduzir tosse, para aumentar expressão de distrofina em músculo de um paciente e para administrar um composto. | |
| MX361542B (es) | Compuestos de morfinan. | |
| IL243574B (en) | A pharmaceutical preparation for use in the treatment of a disease treatable by blocking purine receptors | |
| BR112013013417A2 (pt) | composto, medicamento, métodos para inibir a acetil-coa carboxilase em um mamífero, e de profilaxia ou tratamento da obesidade ou diabete em um mamífero, e, uso de um composto ou sal | |
| EP2229171A4 (en) | METHOD AND COMPOSITIONS FOR TREATING POST-OPERATIVE PAIN WITH A LOCAL ANESTHETIC | |
| BRPI0812504A2 (pt) | Composto, composição farmacêutica e método de profilaxia ou tratamento de doença ou condição associados a receptor de canabinoides em sujeito mamífero | |
| PL2397158T3 (pl) | Skojarzone podawanie związków morfinanów oraz leków przeciwdepresyjnych w leczeniu nietrzymania afektu | |
| BRPI0917004A2 (pt) | composto, composição farmacêutica, uso de um composto, e, métodos para melhorar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero em necessidade deste | |
| BRPI0916890A2 (pt) | composto, composição farmacêutica, métodos para elicitar um efeito agonista, e um efeito antagonista de um receptor de gip, para tratar condições ou doeças, para tratar distúrbios, para tratar ou prevenir causas secundárias de diabete, e para estimular secreção de insulina em um indivíduo, e, uso de um composto | |
| IL213526A0 (en) | Methods for treating acute myocardial infarctions and associated disorders | |
| MX2011008450A (es) | Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos. | |
| BR112013025386A2 (pt) | combinação de um composto, composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, método para tratamento de uma doença ou afecção modulada por mutação braf v600e e altos níveis de pakt em um mamífero e uso | |
| IL205704A (en) | Use of alpha adrenoceptor inhibitors in the preparation of a drug for the treatment of pig fever | |
| BR112013016862A2 (pt) | combinação de um agonista de opioide e um antagonista de opioide no tratamento de doença de parkinson | |
| IL221744A (en) | Use of a combination of compounds to prepare a drug to treat Parkinson's disease | |
| BRPI0922452A2 (pt) | composto, composição farmacêutica, uso em um composto, e método para prevenir, tratar ou melhorar doenças ou condições dérmicas, ou distúrbios de ferimento cutâneo agudos ou crônicos. | |
| HUE050319T2 (hu) | Kompozíciók és eljárások alkoholfogyasztással kapcsolatos rendellenességek, fájdalom és más betegségek kezelésére | |
| EP2190408A4 (en) | ANALGETIC AND ANTI-INFLAMMATORY COMPOSITIONS AND METHOD FOR THE TREATMENT, PREVENTION OR TREATMENT OF PAIN AND IGNITION | |
| IN2012DN02782A (enExample) | ||
| EP2257543A4 (en) | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, PROCESSING METHODS AND PREPARATION METHODS THEREOF | |
| BR112012002246A2 (pt) | composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente | |
| IL209816A0 (en) | Combination of pilocarpin and methimazol for treating charcot-marietooth disease and related disorders | |
| BR112013001422A2 (pt) | metodo para tratar ou previnir disturbios induzidos por l-dopa, agonista dopamina e/ou acentuador de dopamina em um individuo que necessita dos mesmos, agente, composição, uso de ou mais agentes e metodo para tratar a doença de parkinson | |
| IL216258A0 (en) | Serotonin 5-ht3 receptor antagonists for use in the treatment of lesional vestibular disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |